Drug Profile
Research programme: RNA transcription inhibitors - Molecumetics/Bristol Myers Squibb
Latest Information Update: 14 Mar 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Molecumetics
- Class Small molecules
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Immunological disorders; Inflammation
Most Recent Events
- 08 Sep 1999 Preclinical development for Immunological disorders in USA (PO)
- 08 Sep 1999 Preclinical development for Inflammation in USA (PO)